

Cover Story
Clinical
Three years ago, researchers from Memorial Sloan Kettering Cancer Center published stunning results: For the 5% of rectal cancer patients whose tumors are mismatch-repair deficient, neoadjuvant dostarlimab-gxly (Jemperli) has the makings of a silver bullet.
Cancer Policy
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets
Trending Stories
- TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - In The Headlines: Are cancer registries on the chopping block, and what does it mean if they are?
- Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health
- Ci4CC’s 23rd Cancer Center Summit to focus on accelerating oncology innovation through AI